Skip to content

d4T/3TC/nevirapine will be preferred option for 3 x 5

Community mobilisation key to success of 3 x 5

India to begin free HIV treatment programme, will treat 100,000 within a year

HIV testing in Africa: will VCT for all do more than ABC approach?

Tipranavir now available for emergency use in UK

Gastrointestinal side-effects lead one in eight to change HAART regimen in first year of treatment

Warning on Kaletra, tenofovir and ddI interaction after case of multiple severe toxicities

HAART means that HIV-positive patients much less likely to be hospitalised with flu

Revised WHO Treatment Guidelines - deadline for comments 14 November